Expertise in
19
conditions

Dr. Lolie C. Yu

Hematology | Oncology
Children's Hospital New Orleans
200 Henry Clay Ave, 
New Orleans, LA 
Clinical Trials:Currently Recruiting for 6 Trials
Accepting New Patients
42 Years of Experience
Expertise in
19
conditions
Children's Hospital New Orleans
200 Henry Clay Ave, 
New Orleans, LA 

Overview

Lolie Yu is a Hematologist and an Oncologist practicing medicine in New Orleans, Louisiana. She has been practicing medicine for over 42 years.

Dr. Yu is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Hepatoblastoma, Langerhans Cell Histiocytosis, Ependymoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 55 peer reviewed articles and participating in 83 clinical trials. Dr. Yu is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatrics in LA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Children's Hospital New Orleans
200 Henry Clay Ave, New Orleans, LA 70118

Additional Areas of Focus

Dr. Yu has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

82 Clinical Trials

A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Procedure, Radiation
Study Drug: Selinexor
Study Phase: Phase 1/Phase 2
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine
Study Phase: Phase 2
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Device
Study Drug: Busulfan
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
View 4 Less Clinical Trials

55 Total Publications

Factors Associated With Pre-donation Health-related Quality-of-Life Among Pediatric Sibling Hematopoietic Cell Donors: A DonorKids QL Study.
Factors Associated With Pre-donation Health-related Quality-of-Life Among Pediatric Sibling Hematopoietic Cell Donors: A DonorKids QL Study.
Journal: Transplantation and cellular therapy
Published: December 11, 2025
Similar Doctors
Expertise in
31
conditions
Dr. Charles V. Wendling
Hematology | Oncology
Expertise in
31
conditions
Dr. Charles V. Wendling
Hematology | Oncology
Referral may be required

Ochsner Clinic Foundation

1514 Jefferson Hwy, 
New Orleans, LA 
 (3.2 miles away)
504-842-3910
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Charles Wendling is a Hematologist and an Oncologist practicing medicine in New Orleans, Louisiana. Dr. Wendling is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Breast Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Wendling is currently accepting new patients.

Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required
Before you request

Ochsner Medical Center - New Orleans

1514 Jefferson Highway, 
New Orleans, LA 
 (3.2 miles away)
504-842-3910
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marc Matrana is an Oncologist practicing medicine in New Orleans, Louisiana. Dr. Matrana is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Lung Cancer, Adult Soft Tissue Sarcoma, and Nephrectomy. Dr. Matrana is board certified in American Board Of Internal Medicine - Hematology/Oncology and American Board Of Internal Medicine - Internal Medicine. Dr. Matrana is currently accepting new patients.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

Office

150 S Liberty St, 
New Orleans, LA 
 (4.1 miles away)
504-988-6300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nakhle Saba is a Hematologist practicing medicine in New Orleans, Louisiana. Dr. Saba is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Saba is currently accepting new patients.

Frequently Asked Questions about Dr. Lolie C. Yu

How do I make an appointment with Dr. Lolie C. Yu?

You can book an appointment with Dr. Lolie C. Yu by calling their office at 504-896-9740. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lolie C. Yu a top-rated expert for Hepatoblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lolie C. Yu is classified as an Advanced expert for Hepatoblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lolie C. Yu specialize in?

While Dr. Lolie C. Yu is a Hematology, they have specific expertise in Hepatoblastoma, Langerhans Cell Histiocytosis, and Ependymoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Lolie C. Yu participate in research or clinical trials?

Yes. Dr. Lolie C. Yu has published 55 articles and abstracts on conditions like Hepatoblastoma. You can view a list of Dr. Lolie C. Yu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lolie C. Yu accept my insurance?

Dr. Lolie C. Yu accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 504-896-9740 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Yu's expertise for a condition
ConditionClose
      View All 19 Advanced Conditions
      View All 30 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile